IN2012DN00767A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00767A IN2012DN00767A IN767DEN2012A IN2012DN00767A IN 2012DN00767 A IN2012DN00767 A IN 2012DN00767A IN 767DEN2012 A IN767DEN2012 A IN 767DEN2012A IN 2012DN00767 A IN2012DN00767 A IN 2012DN00767A
- Authority
- IN
- India
- Prior art keywords
- therapy
- initiation
- tools
- response
- serum
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 abstract 4
- 230000000977 initiatory effect Effects 0.000 abstract 2
- 102000011690 Adiponectin Human genes 0.000 abstract 1
- 108010076365 Adiponectin Proteins 0.000 abstract 1
- 102000004506 Blood Proteins Human genes 0.000 abstract 1
- 108010017384 Blood Proteins Proteins 0.000 abstract 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 abstract 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 abstract 1
- 102000057248 Lipoprotein(a) Human genes 0.000 abstract 1
- 108010033266 Lipoprotein(a) Proteins 0.000 abstract 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22899409P | 2009-07-28 | 2009-07-28 | |
| PCT/US2010/041714 WO2011014349A1 (en) | 2009-07-28 | 2010-07-12 | Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00767A true IN2012DN00767A (pt) | 2015-06-26 |
Family
ID=43529642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN767DEN2012 IN2012DN00767A (pt) | 2009-07-28 | 2010-07-12 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120178100A1 (pt) |
| EP (1) | EP2460007A4 (pt) |
| CN (1) | CN102576015B (pt) |
| AU (1) | AU2010276665A1 (pt) |
| CA (1) | CA2769462A1 (pt) |
| IN (1) | IN2012DN00767A (pt) |
| WO (1) | WO2011014349A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2679995T3 (es) | 2011-03-11 | 2018-09-03 | Vib Vzw | Moléculas y métodos para la inhibición y detección de proteínas |
| RU2014125071A (ru) * | 2011-11-21 | 2015-12-27 | Новартис Аг | Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa |
| FR3010188B1 (fr) * | 2013-09-05 | 2017-11-24 | Univ Joseph Fourier - Grenoble 1 | Procede theragnostique pour le traitement des rhumatismes inflammatoires chroniques |
| ES3041639T3 (en) * | 2015-09-29 | 2025-11-13 | Univ California | Biomarkers and methods for assessing psoriatic arthritis disease activity |
| US20190148019A1 (en) * | 2016-05-12 | 2019-05-16 | Hoffmann-La Roche Inc. | System for predicting efficacy of a target-directed drug to treat a disease |
| CN109580759A (zh) * | 2017-09-28 | 2019-04-05 | 成都飞机工业(集团)有限责任公司 | 一种四极质谱计 |
| US11232344B2 (en) | 2017-10-31 | 2022-01-25 | General Electric Company | Multi-task feature selection neural networks |
| US12089930B2 (en) | 2018-03-05 | 2024-09-17 | Marquette University | Method and apparatus for non-invasive hemoglobin level prediction |
| KR20210118878A (ko) * | 2019-01-23 | 2021-10-01 | 얀센 바이오테크 인코포레이티드 | 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물 |
| WO2022051245A2 (en) * | 2020-09-01 | 2022-03-10 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
| CN114518416B (zh) * | 2020-11-20 | 2024-05-24 | 上海交通大学医学院附属瑞金医院 | 一种判断银屑病对il-17a抗体应答反应及其复发的标志物 |
| EP4264272B1 (en) * | 2020-12-18 | 2024-09-18 | Nightingale Health Oyj | Method for determining whether a subject is at risk of developing a musculoskeletal and/or connective tissue disease |
| CA3208411A1 (en) * | 2021-02-25 | 2022-09-01 | George C. Lee | Patient response-based biomarker topology quantification and assessment for multiple tissue types |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002048310A2 (en) * | 2000-12-15 | 2002-06-20 | Genetics Institute, Llc | Methods and compositions for diagnosing and treating rheumatoid arthritis |
| US20080026485A1 (en) * | 2006-04-18 | 2008-01-31 | Wolfgang Hueber | Antibody profiling for determination of patient responsiveness |
| TWI500427B (zh) * | 2010-05-14 | 2015-09-21 | Abbvie Inc | Il-1結合蛋白 |
-
2010
- 2010-07-12 WO PCT/US2010/041714 patent/WO2011014349A1/en not_active Ceased
- 2010-07-12 CN CN201080044717.6A patent/CN102576015B/zh not_active Expired - Fee Related
- 2010-07-12 IN IN767DEN2012 patent/IN2012DN00767A/en unknown
- 2010-07-12 CA CA2769462A patent/CA2769462A1/en not_active Abandoned
- 2010-07-12 EP EP10804876.0A patent/EP2460007A4/en not_active Withdrawn
- 2010-07-12 AU AU2010276665A patent/AU2010276665A1/en not_active Abandoned
- 2010-07-12 US US13/386,998 patent/US20120178100A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2460007A4 (en) | 2013-06-19 |
| CA2769462A1 (en) | 2011-02-03 |
| CN102576015A (zh) | 2012-07-11 |
| CN102576015B (zh) | 2014-09-10 |
| US20120178100A1 (en) | 2012-07-12 |
| EP2460007A1 (en) | 2012-06-06 |
| AU2010276665A1 (en) | 2012-02-23 |
| WO2011014349A1 (en) | 2011-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
| BR112015017403A2 (pt) | biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória | |
| IN2014CN04326A (pt) | ||
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| BR112015025407A2 (pt) | método e dispositivo para testar um transformador | |
| MX360564B (es) | Análisis de coagulación de bajo volumen. | |
| WO2008036835A3 (en) | Methods and compositions for upregulation of peroxiredoxin activity | |
| BR112015029852A2 (pt) | método para prever ou monitorar se um paciente que sofre de câncer ou uma doença autoimune responderá ou responde ao tratamento com um agonista de tlr-9, agonista de tlr-9 para uso em um método de tratamento de câncer, e kit para prever ou monitorar se um paciente que sofre de câncer ou doença autoimune irá responder ou responde ao tratamento com um agonista de tlr-9 | |
| BR112013000869A2 (pt) | método para diagnóstico de câncer de próstata (pca) com uma sensibilidade desejada em um sujeito; método para monitorar a progressão do câncer de próstata (pca) em um sujeito; método para avaliar se um sujeito tem que ser submetido a uma biópsia de próstata; kit compreendendo um primeiro componente e, opcionalmente, um segundo componente e uso de um kit | |
| MX2017010569A (es) | Dispositivo, plataforma y ensayo para evaluacion de celulas. | |
| BR112015004631A2 (pt) | marcadores genéticos de resistência à mastite | |
| BR112013004254A2 (pt) | conjunto, método, sistema, e aparelho para avaliação do nível de partículas de lipoproteína específicas presentes em um fluido corporal | |
| BR112018003300A2 (pt) | sistemas e métodos para determinar informação relacionada a uma ordem atual com base em ordens históricas | |
| BR112015021507A2 (pt) | métodos e composições para o diagnóstico de pré-eclampsia | |
| BR112012024175A2 (pt) | hbf e a1m como marcadores de estágio precoce para preeclampsia | |
| BR112014018717A8 (pt) | Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b | |
| BR112013025287A2 (pt) | ensaios com receptores de esteroide para detectar células tumorais | |
| BR112021021574A2 (pt) | Método para identificar uma abordagem reprodutiva em um indivíduo que sofre de uma varicocele | |
| PL419784A1 (pl) | Zastosowanie metabolitów jako biomarkerów do przewidywania porodu przedwczesnego i sposób identyfikacji porodu przedwczesnego | |
| UA109274U (uk) | Спосіб прогнозування розвитку остеопорозу | |
| UA128823U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA108612U (uk) | Спосіб прогнозування розвитку остеопорозу | |
| UA130515U (uk) | Спосіб прогнозування розвитку остеоартрозу | |
| UA82147U (ru) | Способ прогнозирования риска возникновения ишемического инсульта | |
| Morin et al. | Advanced paternal age does not affect embryo development in preimplantation genetic screening cycles |